Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin
dc.contributor.author | Higano, Celestia S. | en_US |
dc.contributor.author | Tangen, Catherine M. | en_US |
dc.contributor.author | Sakr, Wael A. | en_US |
dc.contributor.author | Faulkner, James | en_US |
dc.contributor.author | Rivkin, Saul E. | en_US |
dc.contributor.author | Meyers, Frederick J. | en_US |
dc.contributor.author | Hussain, Maha H. A. | en_US |
dc.contributor.author | Baker, Laurence H. | en_US |
dc.contributor.author | Russell, Kenneth J. | en_US |
dc.contributor.author | Crawford, E. David | en_US |
dc.date.accessioned | 2008-05-12T13:44:11Z | |
dc.date.available | 2009-06-01T20:08:52Z | en_US |
dc.date.issued | 2008-05-15 | en_US |
dc.identifier.citation | Higano, Celestia S.; Tangen, Catherine M.; Sakr, Wael A.; Faulkner, James; Rivkin, Saul E.; Meyers, Frederick J.; Hussain, Maha; Baker, Laurence H.; Russell, Kenneth J.; Crawford, E. David (2008). "Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin." Cancer 112(10): 2181-2187. <http://hdl.handle.net/2027.42/58591> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/58591 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18404692&dopt=citation | en_US |
dc.description.abstract | BACKGROUND. Many patients with invasive urothelial cell cancer are poor candidates for cisplatin-based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address treatment for such patients. METHODS. Eligible patients had primary or recurrent muscle-invasive disease with transitional cell or squamous cell histology, a performance status from 0 to 2, no extrapelvic disease, a life expectancy >3 months, and adequate hematologic function. The treating clinician assigned patients to operable or inoperable groups. All patients received 2 cycles of 5-fluorouracil (5-FU) at a dose of 1000mg/m 2 per day × 4 starting concurrently with radiation at a dose of 200 centigrays per day × 10 each cycle. After 2 cycles, operable patients with positive biopsies underwent cystectomy, and patients with negative biopsies received a third cycle of chemoradiotherapy. Patients in the inoperable group received 3 cycles without interim biopsy. RESULTS. Eighteen of 24 eligible patients in the operable group were evaluable for response. Five patients had a complete response (CR), 9 patients had stable disease, 1 patient had progressive disease, and 3 patients were not assessable. The median progression-free survival was 10 months (95% confidence interval [95% CI], 4–14 months), and the median overall survival was 18 months (95% CI, 7–28 months). In the inoperable group, 35 of 37 eligible patients were evaluable for response with 17 CRs (49%; 95% CI, 31%–66%). The median progression-free survival was 13 months (95% CI, 10–17 months), and the median overall survival was 20 months (95% CI, 11–53 months). There were no episodes of grade 4 toxicity. CONCLUSIONS. In the current study, the combination of 5-FU and radiation was found to be tolerated well by patients with numerous comorbidities who could not tolerate cisplatin-based therapy or cystectomy. Cancer 2008. © 2008 American Cancer Society. | en_US |
dc.format.extent | 168083 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington ; Fax: (210) 677-0006 ; Southwest Oncology Group (SWOG-8733), Operations Office, 14980 Omicron Drive, San Antonio, TX 78245-3217 | en_US |
dc.contributor.affiliationother | Southwest Oncology Group Statistical Center, Seattle, Washington | en_US |
dc.contributor.affiliationother | Department of Pathology, Wayne State University Medical Center, Detroit, Michigan | en_US |
dc.contributor.affiliationother | Southwest Oncology Group Statistical Center, Seattle, Washington | en_US |
dc.contributor.affiliationother | Puget Sound Oncology Consortium, Seattle, Washington | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, University of California at Davis, Sacramento, California | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, Division of Hematology/Oncology, Wayne State University Medical Center, Detroit, Michigan | en_US |
dc.contributor.affiliationother | Department of Radiation Oncology, University of Washington, Seattle, Washington | en_US |
dc.contributor.affiliationother | Department of Surgery, University of Colorado Health Sciences Center, Denver, Colorado | en_US |
dc.identifier.pmid | 18404692 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/58591/1/23420_ftp.pdf | |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.23420 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.